Necitumumab

• Patients with a strong history of heart disease or severe lung disease ( Chronic obstructive pulmonary disease ) should be monitored closely as necitumumab can cause cardiopulmonary arrest or sudden death. • Checking the levels of magnesium, potassium, and calcium before each infusion of necitumumab treatment and for at least eight weeks after taking the last dose of necitumumab is necessa​‍​​​​​‍​‍‍‍‍​‍‍ry to detect and treat if any reports of low levels of magnesium, potassium, and calcium are found. • Treatment with necitumumab can be stopped temporarily, and electrolytes can be given to the patient if such low levels of electrolyte abnormalities are reported. • Patients can experience certain symptoms of heart attack, damage to the heart, lungs or brain due to the interruption of blood supply when treated with necitumumab along with gemcitabine and cisplatin. So, caution is required in treating such patients. • Infusion-related reactions and skin reactions such as rashes, itching, pimples or dry skin have been reported in patients given necitumumab infusion usually within the first two weeks of treatment; if the reactions are severe the treatment can be permanently stopped.